http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6291667-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 1998-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e72b64ea2de1a165c82bf25913d3f00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89fb67c030da30f277ef2b8b30e306c2 |
| publicationDate | 2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6291667-B1 |
| titleOfInvention | Method and composition for treatment of kaposi's sarcoma |
| abstract | A novel method of treating Kaposi's sarcoma (KS) in patients, by administration of an effective amount of VEGF antagonist/s. VEGF antagonists are capable of inhibiting the growth of KS cells in culture by inhibiting the production of VEGF, or by interfering with the binding of VEGF to its cognate receptors or interfere with the biological effects of VEGF. The VEGF antagonist may be administered to KS patients topically, orally, or parentally. Other VEGF antagonist such as VEGF antibodies, VEGF receptor antibodies, soluble forms of VEGF receptors that bind VEGF away from the cells, or agents that inhibit the signal of VEGF into the cell such as protein kinase inhibitors etc. can also be used The novel antisense oligonucleotides (Veglin-1 and Veglin-3) may also be used to inhibit VEGF and thus new blood vessel formation in diseases such as tumors, proliferative retinopathy, or collagen vascular diseases such as rheumatoid arthritis, and skin diseases such as pemphigus and psoriasis. The KS cell lines also allow-the screening of other VEGF inhibitors. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6703020-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010330152-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1564292-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6676941-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2281885-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6524583-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6887468-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7056509-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3168304-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003175276-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002165174-A1 |
| priorityDate | 1997-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.